Effect of traditional Chinese medicine berberine on type 2 diabetes based on comprehensive metabonomics

被引:190
作者
Gu, Yan [1 ,2 ]
Zhang, Yifei [3 ]
Shi, Xianzhe [1 ]
Li, Xiaoying [3 ]
Hong, Jie [3 ]
Chen, Jing [1 ]
Gu, Weigiong [3 ]
Lu, Xin [1 ]
Xu, Guowang [1 ]
Ning, Guang [3 ]
机构
[1] Chinese Acad Sci, Dalian Inst Chem Phys, CAS Key Lab Separat Sci Analyt Chem, 457 Zhongshan Rd, Dalian 116023, Peoples R China
[2] Shenyang Pharmaceut Univ, Sch Pharm, Dept Pharmaceut Anal, Shenyang 110016, Peoples R China
[3] Shanghai Jiao Tong Univ, Sch Med,Shanghai Clin Ctr Endocrine & Metab Dis, Rui Jin Hosp, Shanghai Univ E Inst,Div Endocrine & Metab Dis, Shanghai 200025, Peoples R China
基金
中国国家自然科学基金;
关键词
UPLC/MS; Type; 2; diabetes; Metabonomics; Berberine; Fatty acids; Dyslipidemia; FREE FATTY-ACIDS; INSULIN-RESISTANCE; GLUCOSE-METABOLISM; MASS-SPECTROMETRY; MELLITUS PATIENTS; PROTEIN-KINASE; SECRETION; LIPOTOXICITY; PATHOGENESIS; OBESITY;
D O I
10.1016/j.talanta.2010.01.015
中图分类号
O65 [分析化学];
学科分类号
070302 ; 081704 ;
摘要
A comprehensive metabonomic method, in combination with fingerprint analysis and target analysis, was performed to reveal potential mechanisms of berberine action in the treatment of patients with type 2 diabetes and dyslipidemia. Serum samples of 60 patients before and after treatment with either berberine or placebo were collected. Ultra-performance liquid chromatography and quadrupole time-of-flight tandem mass spectrometry (UPLC Q-TOF MS) coupled with pattern recognition analysis were used to identify changes in global serum metabolites. Compared with placebo, patients before and after berberine treatment could be separated into distinct clusters as displayed by the orthogonal signal correction filtered partial least-squares discriminant analysis (OSC-PLS-DA) score plot, which indicated changes in circulating metabolites after berberine treatment. Among them, free fatty acids changed markedly. These were further quantified by UPLC combined with single quadrupole mass spectrometry (UPLC SQ MS). There was a highly significant decrease in the concentrations of 13 fatty acids following berberine administration. 10 fatty acids also differed statistically from placebo. These results suggest that berberine might play a pivotal role in the treatment of type 2 diabetes through down-regulating the high level of free fatty acids and that comprehensive metabonomic measurements are potentially very useful for studying the mechanisms of action of traditional Chinese medicines. (C) 2010 Elsevier B.V. All rights reserved.
引用
收藏
页码:766 / 772
页数:7
相关论文
共 33 条
[1]  
[Anonymous], J NANJING MED U
[2]   Metabonomic Variations in the Drug-Treated Type 2 Diabetes Mellitus Patients and Healthy Volunteers [J].
Bao, Yuqian ;
Zhao, Tie ;
Wang, Xiaoyan ;
Qiu, Yunping ;
Su, Mingming ;
Jia, Weiping ;
Jia, Wei .
JOURNAL OF PROTEOME RESEARCH, 2009, 8 (04) :1623-1630
[3]   Acute lowering of plasma fatty acids lowers basal insulin secretion in diabetic and nondiabetic subjects [J].
Boden, G ;
Chen, XH ;
Iqbal, N .
DIABETES, 1998, 47 (10) :1609-1612
[4]   Role of fatty acids in the pathogenesis of insulin resistance and NIDDM [J].
Boden, G .
DIABETES, 1997, 46 (01) :3-10
[5]   Free fatty acids in obesity and type 2 diabetes:: defining their role in the development of insulin resistance and β-cell dysfunction [J].
Boden, G ;
Shulman, GI .
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2002, 32 :14-23
[6]  
CHERT MJ, 2006, J PROTEOME RES, V5, P995
[7]   Circulating fatty acids are essential for efficient glucose-stimulated insulin secretion after prolonged fasting in humans [J].
Dobbins, RL ;
Chester, MM ;
Daniels, MB ;
McGarry, JD ;
Stein, DT .
DIABETES, 1998, 47 (10) :1613-1618
[8]   Metabolic fingerprinting as a diagnostic tool [J].
Ellis, David I. ;
Dunn, Warwick B. ;
Griffin, Julian L. ;
Allwood, J. William ;
Goodacre, Royston .
PHARMACOGENOMICS, 2007, 8 (09) :1243-1266
[9]  
Eriksson L., 2001, Umetrics Academy, Umea, P43
[10]   Metabonomics: Its potential as a tool in toxicology for safety assessment and data integration [J].
Griffin, JL ;
Bollard, ME .
CURRENT DRUG METABOLISM, 2004, 5 (05) :389-398